Alverium Health, an innovation in the journey from scientific ambition to commercial reality, is a contract biotech company, led by a highly experienced, functionally diverse team dedicated to creating maximum value for assets, companies and patients through a unique approach to the commercialization journey
An innovation in the journey
from scientific ambition
to commercial reality
The typical drug discovery timeline is lengthy, costly and risky. The average cost to bring an asset to market has increased by 67% since 2010. The average cost to develop a therapeutic asset is estimated at $1.3bn.
LSE, LSH&TM and KUL (2020)
Consider...
Good science, lots of discovery and record funding levels should lead to unlimited potential.
Yet, every year real dollars and value are lost through unmet expectations.
Turning the unrealized opportunity into value is what Alverium was designed to achieve.
“Translating scientific ambition into full commercial potential… ”
We can strategically drive and executionally direct an integrated process to accelerate the journey from concept to commercialization and beyond.
For individuals or organizations who want a more agile and efficient approach to bringing assets to market, while maintaining optionality for individual and corporate goals, we can engage at any stage of the journey to build value with our global strategy and delivery team.
We enable a higher confidence level for commercial success and patient benefit because we:
prioritize activities
that focus on what is
needed to enhance
commercial and
corporate value
follow and
guide the asset
with a seasoned
integrated team
without silos
provide a
one-stop-shop,
on demand
infrastructure and
resource solution
“…ultimately, to accelerate healthcare advances to patients and maximize commercial and corporate value”
A highly experienced, functionally diverse team dedicated to creating maximum value for assets, companies and patients through a unique approach to the commercialization journey
Concept
Concept Inception & Evolution
Clinical
Clinical Development Process
COMMERCIAL
Commercial GTM Strategy, Plans & Execution:
Enabled by data, analytics & proprietary tech platform
We develop strategy and follow it through to tactical plans and execution. Our model augments or replaces internal functions and resources, accelerating progress with cost flexibility and minimal executional complexity, while ensuring corporate runway optionality.
Concept
“Early ideation/
prototype”
Clinical
“Pre-Launch”
De-risked commercial execution, predictable cost structure
Reduced cycle time to IP monetization
Maximized asset and corporate valuations
Risk mitigated investments with enhanced probability of success
Our integrated team will meet the client wherever they are in their journey
Our integrated team will meet the client wherever they are in their journey
Deep integrated expertise, building value at every step
One partner to deliver an asset from discovery to a regional and or global market: avoids the need to engage multiple expert consultants and the struggle to connect them all
Alverium Engagement Experience sits above traditional customer experience: and is paramount from beginning to end; not a separate concept introduced in late-stage commercialization.
Doers not just advisers: Alverium does not just advise a client on how it should/can bring an asset to a global market; Alverium will do it with/for the client
All execution is strategically connected and directed: early involvement of all functional areas and ongoing seamless integration ensures faster time to market and optimal launch performance; no disconnects, no sloppy hand-offs, no competing agendas.
Novel platform strategy
Newly formed cannabinoid platform biotech needed to accelerate clinical to commercial program.
In 4 months, added an exec team that rebranded the company, reprioritized therapeutic focus, evolved clinical development program and launched a raise.
Accelerating commercialization
Emerging biotech bringing therapies to market in the UK and US needed support for a variety of pre-launch activities to meet timelines.
Deployed on-demand team to support key projects from clinical to commercial globally.
Fail fast to pivot
Emerging founder/owner clinical organization of 30, moving to commercial quickly with a novel product used in the ICU.
Immediately inserted clinical to commercial leadership team and brought them to P3 results sooner, which failed. De-risked model allowed them to quickly pivot to focus on their next pipeline asset with minimal cost and operational issues.
Asset funding
Device company on the market in the UK through a distributor, wanting to initiate P3 trials in US and Asia, as well as accelerate sales in Europe.
Lead investment banker brought us on to front the executive team and go on a raise, which resulted in $70M in funding in six weeks.
Resource fill-in
Rare biotech company of 300 moving into first commercial launch with ex-big pharma leaders who wanted a large pharma effort on a budget with efficiencies and speed.
Dropped in medical affairs, marketing, communications, market access, field force leads and brought them to market. Developed award-winning disease education campaign.
Outsourced management
Top 10 pharma company with an emerging CNS pipeline asked for a full out-sourced commercial team to de-risk and accelerate asset investment.
Bespoke on-demand flex exec teams are created to meet current needs and be able to evolve for the future.
If you have an inquiry about Alverium, we’d love to hear from you!
Please complete the form below,
or email us at: info@alveriumhealth.com,
or call us at: +44 (0)207 193 0411
Thank you for your interest.